1. Home
  2. MARA vs LQDA Comparison

MARA vs LQDA Comparison

Compare MARA & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marathon Digital Holdings Inc.

MARA

Marathon Digital Holdings Inc.

HOLD

Current Price

$12.15

Market Cap

5.4B

Sector

Technology

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$86.22

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MARA
LQDA
Founded
2010
2004
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.5B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
MARA
LQDA
Price
$12.15
$86.22
Analyst Decision
Buy
Strong Buy
Analyst Count
12
11
Target Price
$17.85
$41.00
AVG Volume (30 Days)
45.8M
1.5M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.81
EPS
N/A
0.52
Revenue
$907,093,000.00
$158,320,000.00
Revenue This Year
N/A
$278.87
Revenue Next Year
$13.31
$57.13
P/E Ratio
N/A
$171.21
Revenue Growth
38.20
1031.18
52 Week Low
$6.66
$16.83
52 Week High
$23.45
$90.90

Technical Indicators

Market Signals
Indicator
MARA
LQDA
Relative Strength Index (RSI) 46.54 62.05
Support Level $11.65 $70.28
Resistance Level $13.69 N/A
Average True Range (ATR) 0.96 5.34
MACD 0.02 0.37
Stochastic Oscillator 41.51 75.85

Price Performance

Historical Comparison
MARA
LQDA

About MARA Marathon Digital Holdings Inc.

MARA Holdings Inc leverages digital asset computing to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for Bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: